Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.

Literature DB >> 20611035

Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.

James H Willig, Christa R Nevin, James L Raper, Michael S Saag, Michael J Mugavero, Amanda L Willig, Jeffrey H Burkhardt, Joseph E Schumacher, Victoria A Johnson.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20611035 PMCID： PMC2901889 DOI： 10.1097/QAI.0b013e3181d01d1d

Source DB: PubMed Journal: J Acquir Immune Defic Syndr ISSN： 1525-4135 Impact factor: 3.731

× No keyword cloud information.

11 in total

1. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay.

Authors: Viviane Lima; Richard Harrigan; Julio S G Montaner
Journal: J Acquir Immune Defic Syndr Date: 2009-05-01 Impact factor: 3.731

2. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor.

Authors: Hiroyuki Gatanaga; Kunihisa Tsukada; Haruhito Honda; Junko Tanuma; Hirohisa Yazaki; Tamayo Watanabe; Miwako Honda; Katsuji Teruya; Yoshimi Kikuchi; Shinichi Oka
Journal: Clin Infect Dis Date: 2009-01-15 Impact factor: 9.079

3. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay.

Authors: Erasmus Smit; Sanjay Bhattacharya; Husam Osman; Steve Taylor
Journal: J Acquir Immune Defic Syndr Date: 2009-07-01 Impact factor: 3.731

4. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.

Authors: W A O'Brien; P M Hartigan; E S Daar; M S Simberkoff; J D Hamilton
Journal: Ann Intern Med Date: 1997-06-15 Impact factor: 25.391

5. Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: Comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays--LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5.

Authors: Antigoni Katsoulidou; Maria Petrodaskalaki; Vana Sypsa; Eleni Papachristou; Cleo G Anastassopoulou; Panagiotis Gargalianos; Anastasia Karafoulidou; Marios Lazanas; Theodoros Kordossis; Anastasia Andoniadou; Angelos Hatzakis
Journal: J Virol Methods Date: 2005-09-27 Impact factor: 2.014

6. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.

Authors: F Damond; B Roquebert; A Bénard; G Collin; M Miceli; P Yéni; F Brun-Vezinet; D Descamps
Journal: J Clin Microbiol Date: 2007-08-22 Impact factor: 5.948

7. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Authors: D A Katzenstein; S M Hammer; M D Hughes; H Gundacker; J B Jackson; S Fiscus; S Rasheed; T Elbeik; R Reichman; A Japour; T C Merigan; M S Hirsch
Journal: N Engl J Med Date: 1996-10-10 Impact factor: 91.245

8. Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay.

Authors: Anthony R Oliver; Spyridon F Pereira; Duncan A Clark
Journal: J Clin Microbiol Date: 2007-09-05 Impact factor: 5.948

9. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification.

Authors: Maya L Petersen; Mark J van der Laan; Sonia Napravnik; Joseph J Eron; Richard D Moore; Steven G Deeks
Journal: AIDS Date: 2008-10-18 Impact factor: 4.177

10. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA.

Authors: H J Lin; L E Myers; B Yen-Lieberman; F B Hollinger; D Henrard; C J Hooper; R Kokka; S Kwok; S Rasheed; M Vahey
Journal: J Infect Dis Date: 1994-09 Impact factor: 5.226

6 in total

1. Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Authors: Luke C Swenson; Bryan Cobb; Anna Maria Geretti; P Richard Harrigan; Mario Poljak; Carole Seguin-Devaux; Chris Verhofstede; Marc Wirden; Alessandra Amendola; Jurg Boni; Thomas Bourlet; Jon B Huder; Jean-Claude Karasi; Snjezana Zidovec Lepej; Maja M Lunar; Odette Mukabayire; Rob Schuurman; Janez Tomazic; Kristel Van Laethem; Linos Vandekerckhove; Annemarie M J Wensing
Journal: J Clin Microbiol Date: 2013-12-04 Impact factor: 5.948

2. Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.

Authors: James H Willig; Inmaculada Aban; Christa R Nevin; Jiatao Ye; James L Raper; James A McKinnel; Lori L Delaitsch; Joseph M Mrus; Guy R De La Rosa; Michael J Mugavero; Michael S Saag
Journal: AIDS Res Hum Retroviruses Date: 2010-10-21 Impact factor: 2.205